Reinfection Rate of Hepatitis C in HIV-1 Positive Men Who Have Sex with Men: A Systematic Review and Meta-analysis

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Aug 15

PMID 35968434

Authors

Zhengwei Wan

Ping Sun

Emmanuel Enoch Dzakah

Liping Huang

Ping Shuai

Yuping Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: A reduction of 80% in new Hepatitis C virus (HCV) infection is expected by 2030. However, high HCV reinfection rates have been reported among the high-risk population. This meta-analysis aimed to assess the HCV reinfection rate after successful treatment of HIV-1 coinfected MSM populations.

Methods: Bibliographic databases were searched and a random-effect model was utilized to calculate the pooled HCV reinfection rate. Sub-group and meta-regression were used to explore heterogeneity among selected studies. A funnel plot and Egger's regression test were performed to estimate the publication bias.

Results: Sixteen studies with 9,017.2 person-years (PY) follow-up were included. The overall HCV reinfection rate following successful treatment among HIV-1-infected MSM was 5.27/100 PY (95% CI, 3.98, 6.96). Lower reinfection rates were observed in developed parts of Europe (5.28/100 PY; 95% CI, 3.73, 6.84) and North America (3.92/100 PY; 95% CI, 1.67, 6.17). Reinfection rates among people with HCV test intervals of fewer than 6 months (7.59/100 PY; 95% CI: 5.15, 10.03) were significantly higher than those with more than 6 months test interval (2.88/100 PY; 95% CI: 2.26, 3.50), with an adjusted RR of 1.86 (95% CI, 1.06, 3.13). The adjusted study factors explained 91.03% the of studies' heterogeneity.

Conclusion: HCV reinfection rate was high in successfully treated MSM who were coinfected with HIV-1. A shorter HCV test interval may help to explore more HCV reinfections. HCV reinfection rate studies from HIV-1 coinfected MSM in underdeveloped countries are urgently needed.

Meta Registration: PROSPERO: CRD42021285206, URL: https://www.crd.york.ac.uk/prospero/.

Citing Articles

Elimination of hepatitis C in a hospital characterized by infectious diseases.

Han Y, Zheng M, Meng H, Han J, Chen J, Wang Y Front Public Health. 2023; 11:1093578.

PMID: 37006527 PMC: 10061059. DOI: 10.3389/fpubh.2023.1093578.

References

Pradat P, Huleux T, Raffi F, Delobel P, Valantin M, Poizot-Martin I . Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018; 32(8):1077-1082. DOI: 10.1097/QAD.0000000000001789. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Jin F, Dore G, Matthews G, Luhmann N, Macdonald V, Bajis S . Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 6(1):39-56. DOI: 10.1016/S2468-1253(20)30303-4. View

Macaskill P, Walter S, Irwig L . A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001; 20(4):641-54. DOI: 10.1002/sim.698. View

Cotte L, Cua E, Reynes J, Raffi F, Rey D, Delobel P . Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int. 2018; . DOI: 10.1111/liv.13922. View

Akiyama M, Lipsey D, Heo M, Agyemang L, Norton B, Hidalgo J . Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy. Clin Infect Dis. 2019; 70(12):2695-2702. PMC: 7456350. DOI: 10.1093/cid/ciz693. View

Chaillon A, Sun X, Cachay E, Looney D, Wyles D, Garfein R . Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019; 6(4):ofz160. PMC: 6483132. DOI: 10.1093/ofid/ofz160. View

Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J . Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis. 2017; 64(9):1154-1162. PMC: 5399935. DOI: 10.1093/cid/cix126. View

Boyd A, Miailhes P, Chas J, Valantin M, Yazdanpanah Y, Rosenthal E . Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. J Antimicrob Chemother. 2020; 75(7):1961-1968. DOI: 10.1093/jac/dkaa091. View

10.

Booth R, Lehman W, Kwiatkowski C, Brewster J, Sinitsyna L, Dvoryak S . Stimulant injectors in Ukraine: the next wave of the epidemic?. AIDS Behav. 2008; 12(4):652-61. DOI: 10.1007/s10461-008-9359-3. View

11.

Stanaway J, Flaxman A, Naghavi M, Fitzmaurice C, Vos T, Abubakar I . The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388(10049):1081-1088. PMC: 5100695. DOI: 10.1016/S0140-6736(16)30579-7. View

12.

Berenguer J, Gil-Martin A, Jarrin I, Montes M, Dominguez L, Aldamiz-Echevarria T . Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS. 2019; 33(4):685-689. DOI: 10.1097/QAD.0000000000002103. View

13.

Chen T, Ding E, Seage Iii G, Kim A . Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009; 49(10):1605-15. PMC: 2805261. DOI: 10.1086/644771. View

14.

Hajarizadeh B, Cunningham E, Valerio H, Martinello M, Law M, Janjua N . Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2019; 72(4):643-657. DOI: 10.1016/j.jhep.2019.11.012. View

15.

Ropelewski L, Mancha B, Hulbert A, Rudolph A, Martins S . Correlates of risky injection practices among past-year injection drug users among the US general population. Drug Alcohol Depend. 2011; 116(1-3):64-71. PMC: 3090520. DOI: 10.1016/j.drugalcdep.2010.11.025. View

16.

Thein H, Yi Q, Dore G, Krahn M . Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22(15):1979-91. DOI: 10.1097/QAD.0b013e32830e6d51. View

17.

Marco A, Guerrero R, Vergara M, Gallego C, Sole C, Planella R . Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016. Int J Drug Policy. 2019; 72:189-194. DOI: 10.1016/j.drugpo.2019.05.014. View

18.

Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C . Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(7):797-808. DOI: 10.1016/S1473-3099(15)00485-5. View

19.

Martin T, Martin N, Hickman M, Vickerman P, Page E, Everett R . Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013; 27(16):2551-7. DOI: 10.1097/QAD.0b013e32836381cc. View

20.

Lambers F, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K . Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011; 25(17):F21-7. DOI: 10.1097/QAD.0b013e32834bac44. View